3-<2-Diaethylamino-aethyl>-5.5-diphenyl-hydantoin | 34341-24-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑烷类
• 英文名称: 3-<2-Diaethylamino-aethyl>-5.5-diphenyl-hydantoin
• 英文别名: 3-<2-Dimethylamino-aethyl>-5.5-diphenyl-hydantoin；3-(2-diethylamino-ethyl)-5,5-diphenyl-imidazolidine-2,4-dione；3-(2-Diaethylamino-aethyl)-5,5-diphenyl-imidazolidin-2,4-dion；Hydantoin, 3-(2-(diethylamino)ethyl)-5,5-diphenyl-；3-[2-(diethylamino)ethyl]-5,5-diphenylimidazolidine-2,4-dione
• CAS: 34341-24-7
• 化学式: C₂₁H₂₅N₃O₂
• 分子量: 351.448
• InChiKey: CCHIICCEKRYUNR-UHFFFAOYSA-N

物化性质

• 熔点：
  121-122 °C
• 密度：
  1.146±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.1
• 重原子数：
  26
• 可旋转键数：
  7
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  52.6
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  3-<2-Diaethylamino-aethyl>-5.5-diphenyl-hydantoin 在 氢氧化钾 作用下， 生成 [N'-(2-diethylamino-ethyl)-ureido]-diphenyl-acetic acid
  参考文献：
  名称：

  Chiti; Sellerie, Farmaco, Edizione Scientifica, 1958, vol. 13, p. 590,600

  摘要：

  DOI：
• 作为产物：
  描述：

  苯妥英 、 N,N-二乙基氯乙胺 在 sodium hydroxide 作用下， 生成 3-<2-Diaethylamino-aethyl>-5.5-diphenyl-hydantoin
  参考文献：
  名称：

  Hoffmann, Bulletin de la Societe Chimique de France, 1950, p. 45

  摘要：

  DOI：

文献信息

• Synthesis, single-crystal, in vitro antitumor evaluation and molecular docking of 3-substitued 5,5-diphenylimidazolidine-2,4-dione derivatives
  作者：Amer M. Alanazi、Adel S. El-Azab、Ibrahim A. Al-Swaidan、Azza R. Maarouf、Eman R. El-Bendary、Mohamed A. Abu El-Enin、Alaa A.-M. Abdel-Aziz

  DOI：10.1007/s00044-013-0597-1

  日期：2013.12

  Series of 3-alkyl, 3-aryl-5,5-diphenylimidazolidine-2,4-diones (2-8) and 3-phenacyl-5,5-diphenylimidazolidine-2,4-diones (9-20) were designed, synthesized, and tested for their antitumor activity. The 13 compounds (3-8, 10-15 and 20) were selected by National Cancer Institute (USA) on the basis of degree of the structure variation and computer modeling techniques for evaluation of their antineoplastic activity. A single dose (10 mu M) of the tested compounds was used in the National Cancer Institute (NCI) 60 cell lines panel assay selected from different nine organs. The tested compounds possessed selective activity against the renal cancer (A498 and UO-31) cell lines. Interestingly, compound 13 showed moderate selective activities towards A498 and UO-31 cell lines, in addition to strong activity against melanoma (MDA-MB-435) cell line and breast cancer cell lines (MCF7) in 114 and 70 %, respectively. Molecular docking study was performed for the most active compound 13 to identify the structural features required for the antitumor activity. The results achieved can be used as a useful template for future development and further derivatization or modification to obtain more potent and selective antitumor agents.The development of novel molecules containing imidazolidine-2,4-dione pharmacophore have shown promising antitumor activities. Compound 13 exploited broad spectrum and potent antitumor activity with the percentages of inhibition range of 28-114 %.
• Chiti; Selleri, Farmaco, Edizione Scientifica, 1958, vol. 13, p. 261,282
  作者：Chiti、Selleri

  DOI：——

  日期：——
• Hoffmann, Bulletin de la Societe Chimique de France, 1950, p. 45
  作者：Hoffmann

  DOI：——

  日期：——
• Chiti; Sellerie, Farmaco, Edizione Scientifica, 1958, vol. 13, p. 590,600
  作者：Chiti、Sellerie

  DOI：——

  日期：——